These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12010505)

  • 21. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
    Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
    J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion.
    Nie H; Evans AA; London WT; Block TM; Ren XD
    J Hepatol; 2012 Apr; 56(4):795-802. PubMed ID: 22173170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
    Yoo BC; Kim HJ; Do JH; Park SM
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):381-8. PubMed ID: 12506242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of hepatitis B virus precore and core promoter variants in Korean patients with chronic hepatitis B.
    Yim SY; Um SH; Young Jung J; Kim TH; Kim JD; Keum B; Seo YS; Yim HJ; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Clin Gastroenterol; 2015 Jan; 49(1):61-8. PubMed ID: 24406435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea.
    Yoo BC; Park JW; Kim HJ; Lee DH; Cha YJ; Park SM
    J Hepatol; 2003 Jan; 38(1):98-103. PubMed ID: 12480566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha.
    Habersetzer F; Zoulim F; Jusot JF; Zhang X; Trabaud MA; Chevallier P; Chevallier M; Ahmed SN; Sepetjan M; Comanor L; Minor J; Trépo C
    J Viral Hepat; 1998 Nov; 5(6):407-14. PubMed ID: 9857350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus precore/core variation and interferon therapy.
    Fattovich G; McIntyre G; Thursz M; Colman K; Giuliano G; Alberti A; Thomas HC; Carman WF
    Hepatology; 1995 Nov; 22(5):1355-62. PubMed ID: 7590647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B.
    Lin CL; Liao LY; Liu CJ; Chen PJ; Lai MY; Kao JH; Chen DS
    J Gastroenterol; 2002; 37(4):283-7. PubMed ID: 11993512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    J Med Virol; 2003 Jul; 70(3):355-60. PubMed ID: 12766997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
    Guptan RC; Thakur V; Kazim SN; Sarin SK
    J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients.
    Choi JW; Ahn SH; Park JY; Chang HY; Kim JK; Baatarkhuu O; Kim DY; Han KH; Chon CY
    J Med Virol; 2009 Apr; 81(4):594-601. PubMed ID: 19235871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B.
    Marrone A; Zampino R; Portella G; Grimaldi M; Durante-Mangoni E; Santarpia L; Ruggiero G; Utili R
    J Viral Hepat; 2005 Mar; 12(2):186-91. PubMed ID: 15720534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of basal core promoter and precore mutations in Chinese chronic hepatitis B patients and correlation with serum HBeAG titers.
    Qin Y; Zhang J; Mao R; Guo H; Yin Y; Wu X; Weng X; Wands J; Tong S
    J Med Virol; 2009 May; 81(5):807-14. PubMed ID: 19319958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B.
    Kanai K; Kako M; Aikawa T; Hino K; Tsubouchi H; Takehira Y; Iwabuchi S; Kawasaki T; Tsuda F; Okamoto H; Miyakawa Y; Mayumi M
    Am J Gastroenterol; 1996 Oct; 91(10):2150-6. PubMed ID: 8855739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.
    Ferns RB; Naoumov NV; Gilson RJ; Tedder RS
    J Clin Virol; 2007 Jul; 39(3):199-204. PubMed ID: 17526429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.
    Hsu HY; Tsai HY; Wu TC; Chiang CL; Ni YH; Chen PJ; Chang MH
    Liver Int; 2008 Nov; 28(9):1288-97. PubMed ID: 18397229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
    Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
    Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.
    Wai CT; Chu CJ; Hussain M; Lok AS
    Hepatology; 2002 Dec; 36(6):1425-30. PubMed ID: 12447868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.